Tests azithromycin in adults with advanced HIV disease
Tests a daily pill against placebo in adults with advanced HIV disease.
Plain-language title generated from the registry record
Registry title: Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)
Key facts
- Where
- Abuja, Calabar, Enugu, Ibadan, Jos, Kano, Lago, Sokoto, Umuahia, Uyo, and Yenagoa, NigeriaSee the 11 sites
- Phase
- Phase 3
Where in Nigeria
- University of Abuja Teaching HospitalAbuja, NigeriaNot yet recruiting
- University of Calabar Teaching HospitalCalabar, NigeriaNot yet recruiting
- University of Nigeria Teaching HospitalEnugu, NigeriaTaking people
- University College HospitalIbadan, NigeriaTaking people
- Jos University Teaching HospitalJos, NigeriaNo longer taking part
- Aminu Kano Teaching HospitalKano, NigeriaNot yet recruiting
- Lagos University Teaching HospitalLago, NigeriaTaking people
- Usmanu Danfodiyo University Teaching HosSokoto, NigeriaNo longer taking part
- Federal Medical CenterUmuahia, NigeriaNot yet recruiting
- University of Uyo Teaching HospitalUyo, NigeriaNo longer taking part
- Niger Delta University Teaching HospitalYenagoa, NigeriaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Population Health Research Institute
- Trial code
- NCT05580666
- Record updated
- 3 September 2025
- Original description
A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.Read full original descriptionShow less
Reducing Mortality in Adults With Advanced HIV Disease, a Double Blinded Randomized Trial
A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.
Inclusion: Age ≥ 18 years; Documented HIV infection; CD4 count criteria:; CD4 count ≤ 100 cells/mm3 within past 4 weeks; or; Documented CD4 nadir ≤ 100 cells/mm3 and complete interruption of ART for ≥ 6 months; or; Documented CD4 count ≤ 100 cells/mm3 if ART-naive; Ability to initiate or re-initiate ART, or switch to an effective ART regimen if failing current therapy, within 4 weeks of enrolment.
Exclusion: Off-label azithromycin prophylaxis or requirement for prolonged (> 7 days) azithromycin (or macrolide) therapy; Severe illness requiring immediate or continued hospitalization (this will be in the judgment of site investigators); Contraindications to azithromycin:; Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic; or; Personal or family history of QT-prolongation.